53906-84-6

Basic information

• Product Name: 2-bromo-1,3-dimethyl-5-nitrobenzene
• Synonyms: 2-bromo-1,3-dimethyl-5-nitrobenzene
• CAS NO: 53906-84-6
• Molecular Formula: C₈H₈BrNO₂
• Molecular Weight: 230.0586
• Mol File: 53906-84-6.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 301.5 °C at 760 mmHg
• Flash Point: 136.2 °C
• Appearance: /
• Density: 1.533 g/cm³
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• CAS DataBase Reference: 2-bromo-1,3-dimethyl-5-nitrobenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 2-bromo-1,3-dimethyl-5-nitrobenzene(53906-84-6)
• EPA Substance Registry System: 2-bromo-1,3-dimethyl-5-nitrobenzene(53906-84-6)

Safety Data

• Hazardous Substances Data: 53906-84-6(Hazardous Substances Data)

Usage

General Description

2-bromo-1,3-dimethyl-5-nitrobenzene is a chemical compound with the molecular formula C8H8BrNO2. It is a yellow crystalline solid with a molecular weight of 218.06 g/mol. 2-bromo-1,3-dimethyl-5-nitrobenzene is used in organic synthesis and is known for its potential applications in pharmaceuticals and agrochemicals. It is a derivative of benzene with a bromine atom at the 2-position and nitro and methyl groups at the 5- and 1,3- positions, respectively. The presence of the bromine atom and nitro group gives this compound its reactive nature, making it useful in the production of various organic compounds. Additionally, it is important for its use as a precursor in the synthesis of more complex compounds.

Upstream product

• 87-62-7 2,6-dimethylaniline 
• 1073338-97-2 2-bromo-1,3-dimethyl-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzene 
• 576-22-7 2-Bromo-m-xylene 
• 2423-71-4 2,6-dimethyl-4-nitro phenol 
• 294853-97-7 N-(4-amino-2,6-dimethylphenyl)-4-methylbenzenesulfonamide 
• 4703-15-5 N-(2,6-dimethylphenyl)-4-methylbenzenesulfonamide 
• 195389-20-9 3-bromo-2,4-dimethyl-6-nitro-aniline 
• 16947-63-0 2,6-dimethyl-4-nitroaniline 
• 156740-78-2 2,6-dimethyl-4-nitrophenyl trifluoromethanesulphonate 
• 195383-84-7 acetic acid-(3-bromo-2,4-dimethyl-anilide) 
• 59557-90-3 4-bromo-3,5-dimethylaniline 

Downstream Products

• 59557-90-3 4-bromo-3,5-dimethylaniline 
• 685507-24-8 (2,6-dimethyl-4-nitrophenyl)phenylcyanomethane-d 
• 866787-37-3 2-bromo-1-(bromomethyl)-3-methyl-5-nitrobenzene 
• 1425187-97-8 2,6-dimethyl-4-nitrophenyl (4'-nitrophenyl) sulfide 
• 114660-00-3 2,6-dimethyl-4-nitrophenyl (phenyl) sulfide 
• 1425187-94-5 2,6-dimethyl-4-nitrophenyl(phenyl)sulfoxide 
• 1425188-03-9 C₈H₈⁽¹⁸⁾FNO₂ 
• 1425187-95-6 2,6-dimethyl-4-nitrophenyl(4'-nitrophenyl)sulfoxide 
• 347190-92-5 2,5-bis(2,6-dimethyl-4-N,N'-di-BOCguanidinophenyl)furan 
• 347190-86-7 2,5-bis(4-amino-2,6-dimethylphenyl)furan 
• 347190-81-2 2,5-bis(2,6-dimethyl-4-nitrophenyl)furan 

Relevant articles and documents

meta-Nitration of Arenes Bearing ortho/para Directing Group(s) Using C?H Borylation

Herein, we report the meta-nitration of arenes bearing ortho/para directing group(s) using the iridium-catalyzed C?H borylation reaction followed by a newly developed copper(II)-catalyzed transformation of the crude aryl pinacol boronate esters into the corresponding nitroarenes in a one-pot fashion. This protocol allows the synthesis of meta-nitrated arenes that are tedious to prepare or require multistep synthesis using the existing methods. The reaction tolerates a wide array of ortho/para-directing groups, such as ?F, ?Cl, ?Br, ?CH3, ?Et, ?iPr ?OCH3, and ?OCF3. It also provides regioselective access to the nitro derivatives of π-electron-deficient heterocycles, such as pyridine and quinoline derivatives. The application of this method is demonstrated in the late-stage modification of complex molecules and also in the gram-scale preparation of an intermediate en route to the FDA-approved drug Nilotinib. Finally, we have shown that the nitro product obtained by this strategy can also be directly converted to the aniline or hindered amine through Baran's amination protocol.

Glucagon Receptor Modulators

The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, A1, A2, A3, A4, L, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.

Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders

Aryl sulfonamide and sulfonyl compounds as modulators of peroxisome proliferator activated receptors, pharmaceutical compositions comprising the same, and methods of treating disease using the same are disclosed.